Show simple item record

dc.contributor.authorDas, M
dc.contributor.authorMamnoon, F
dc.contributor.authorMansoor, H
dc.contributor.authorMeneguim, AC
dc.contributor.authorSingh, P
dc.contributor.authorShah, I
dc.contributor.authorRavi, S
dc.contributor.authorKalon, S
dc.contributor.authorHossain, FN
dc.contributor.authorFerlazzo, G
dc.contributor.authorIsaakidis, P
dc.contributor.authorFurin, J
dc.contributor.authorAcharya, S
dc.contributor.authorThakur, HP
dc.date.accessioned2021-02-23T21:57:21Z
dc.date.available2021-02-23T21:57:21Z
dc.date.issued2020-12-01
dc.date.submitted2021-02-01
dc.identifier.urihttp://hdl.handle.net/10144/619860
dc.description.abstractSETTING: Médecins Sans Frontières (MSF) clinic in Mumbai, India. OBJECTIVE: To determine the final treatment outcomes, culture conversion and adverse events (AEs) during treatment among children and adolescents (0–19 years) with rifampicin-resistant tuberculosis (RR-TB) who received ambulatory injectable-free treatment, including bedaquiline (BDQ) and/or delamanid (DLM) during September 2014–January 2020. DESIGN: This was a retrospective cohort study based on review of routinely collected programme data. RESULTS: Twenty-four patients were included; the median age was 15.5 years (min-max 3–19) and 15 (63%) were females. None were HIV-coinfected. All had fluoroquinolone resistance. Twelve received treatment, including BDQ and DLM, 11 received DLM and one BDQ. The median exposure to BDQ (n = 13) and DLM (n = 23) was 82 (IQR 80–93) and 82 (IQR 77–96) weeks, respectively. Seventeen (94%) patients with positive culture at baseline (n = 18) had negative culture during treatment; median time for culture-conversion was 7 weeks (IQR 5–11). Twenty-three (96%) had successful treatment outcomes: cured (n = 16) or completed treatment (n = 7); one died. Eleven (46%) had 17 episodes of AEs. Two of 12 serious AEs were associated with new drugs (QTcF >500 ms). CONCLUSION: Based on one of the largest global cohorts of children and adolescents to receive new TB drugs, this study has shown that injectable-free regimens containing BDQ and/or DLM on ambulatory basis were effective and well-tolerated among children and adolescents and should be made routinely accessible to these vulnerable groups.en_US
dc.language.isoenen_US
dc.publisherInternational Union Against Tuberculosis and Lung Diseaseen_US
dc.rightsWith thanks to the International Union Against Tuberculosis and Lung Disease.en_US
dc.titleNew TB drugs for the treatment of children and adolescents with rifampicin-resistant TB in Mumbai, Indiaen_US
dc.identifier.journalThe International Journal of Tuberculosis and Lung Diseaseen_US
refterms.dateFOA2021-02-23T21:57:21Z


Files in this item

Thumbnail
Name:
Das et al 2020 New TB drugs for ...
Size:
227.4Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record